Here is the synopsis of our sample research paper on Roche Holdings. Have the paper e-mailed to you 24/7/365.
Essay / Research Paper Abstract
This 16 page paper is an examination of the financial performance and prospects of the Swiss healthcare company Roche Holdings. The paper starts by looking at the recent developments such as drug developments and the way sales have performed since the 2002 annual accounts. The paper then undertakes an in-depth financial analysis. The bibliography cites 12 sources.
Page Count:
16 pages (~225 words per page)
File: TS14_TEroche1.rtf
Buy This Term Paper »
Unformatted sample text from the term paper:
development new healthcare solutions (Roche, 2003). This is undertaken through three business units; Pharmaceuticals, the division that researches develops and manufactures and also markets prescription drugs that
are aimed at being cost effective (Roche, 2003); Diagnostics, which provides systems and equipment to diagnose conditions as well as healthcare decision making support system (Roche, 2003); and finally
Vitamins and Fine Chemicals, the smallest of the units which supplies bulk vitamins and carotenoids to the cosmetics industry, the pharmaceutical industry, and the feed and food industries (Roche, 2003).
For a potential investor they will be interested in both the past performance and also the information that may impact on the future performances, information which may not
be reflected in the latest set of accounts. Any company in the pharmaceutical industry is likely to have a greater level of fluctuation in results due to the nature of
research and development, especially in drugs. Therefore for this industry it is important to assess the development that are taking places and look at sales which are at the beginning
of their lifecycles prior to the loss of patents. First we will consider the recent new and the way this may be interpreted before looking at the bigger picture
so that the movements and trends may be paced in a wider context and assessed as a potential investment. 2. General Performance The group itself has been showing
very good results in 2003, the total sales are up by 19% when measured in local currencies, however, when in Swiss Francs this is only 10%, but this is still
a very good increase and out performs the industries averages which are nowhere near double figures (Roche, 2003). The highest level of growth is in the pharmaceutical division, by
...